1 – 250 of 556
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Blodtest – fönster till hjärnan vid Alzheimers sjukdom
(
- Contribution to journal › Scientific review
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
(
- Contribution to journal › Article
-
Mark
In vivo detection of Alzheimer's and Lewy body disease concurrence : Clinical implications and future perspectives
(
- Contribution to journal › Scientific review
-
Mark
Structural and functional connectivity associations with anterior cingulate sulcal variability
2024) In Brain Structure and Function(
- Contribution to journal › Article
-
Mark
The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology
(
- Contribution to journal › Article
-
Mark
Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App NL−F/NL−F mice
(
- Contribution to journal › Article
-
Mark
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers : A Secondary Analysis of a Randomized Clinical Trial
2024) In JAMA Neurology(
- Contribution to journal › Article
-
Mark
Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
(
- Contribution to journal › Article
-
Mark
Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study
(
- Contribution to journal › Article
-
Mark
Prognostic and Predictive Factors in Early Alzheimer's Disease : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Divergent functional connectivity changes associated with white matter hyperintensities
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
(
- Contribution to journal › Article
-
Mark
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
2024) In Journal of Neurology(
- Contribution to journal › Article
-
Mark
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
(
- Contribution to journal › Article
-
Mark
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
(
- Contribution to journal › Article
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease
2024) In bioRxiv : the preprint server for biology(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024) In JAMA(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
2024) In Nature Aging(
- Contribution to journal › Article
-
Mark
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
(
- Contribution to journal › Article
-
Mark
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
(
- Contribution to journal › Article
-
Mark
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests
2024) In Nature Medicine(
- Contribution to journal › Article
-
Mark
Biomarker-based staging of Alzheimer disease : rationale and clinical applications
(
- Contribution to journal › Scientific review
-
Mark
Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(
- Contribution to journal › Article
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
(
- Contribution to journal › Scientific review
-
Mark
Novel avenues of tau research
(
- Contribution to journal › Scientific review
-
Mark
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
(
- Contribution to journal › Article
-
Mark
Clinical recognition of frontotemporal dementia with right anterior temporal predominance : A multicenter retrospective cohort study
2024) In Alzheimer's and Dementia(
- Contribution to journal › Article
-
Mark
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
(
- Contribution to journal › Article
- 2023
-
Mark
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
(
- Contribution to journal › Scientific review
-
Mark
Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
‘Proactive aging’ is a new research approach for a new era
(
- Contribution to journal › Letter
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Polygenic risk of type 2 diabetes is associated with incident vascular dementia : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Article
-
Mark
Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
MRI BrainAGE demonstrates increased brain aging in systemic lupus erythematosus patients
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
2023) In Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 43(4). p.565-580(
- Contribution to journal › Article
-
Mark
Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors
(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
CenTauR : Toward a universal scale and masks for standardizing tau imaging studies
(
- Contribution to journal › Article
-
Mark
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Donanemab in Early Symptomatic Alzheimer Disease : The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
(
- Contribution to journal › Article
-
Mark
Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The molecular genetic landscape of human brain size variation
(
- Contribution to journal › Article
-
Mark
European consensus for the diagnosis of MCI and mild dementia : Preparatory phase
(
- Contribution to journal › Article
-
Mark
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
(
- Contribution to journal › Article
- 2022
-
Mark
Subtypes of Alzheimer's disease : questions, controversy, and meaning
(
- Contribution to journal › Article
-
Mark
Novel insights regarding the measurement properties of the SCOPA-AUT
(
- Contribution to journal › Article
-
Mark
Tau biomarkers in Alzheimer's disease : towards implementation in clinical practice and trials
(
- Contribution to journal › Scientific review
-
Mark
Tau PET Imaging in Neurodegenerative Disorders
2022) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 63. p.20-26(
- Contribution to journal › Article
-
Mark
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
(
- Contribution to journal › Article
-
Mark
The mean diffusion propagator model revealed cortical microstructural changes associated with both amyloid-β and tau pathology and astroglial activation
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages : Implications for Clinical Alzheimer Trials
(
- Contribution to journal › Article
-
Mark
Spatial Navigation and Its Association with Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia
(
- Contribution to journal › Article
-
Mark
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease : Long-Term Observation and Implications of Clinical Subtypes
(
- Contribution to journal › Article
-
Mark
Comparison of risk factors for Parkinson's disease, coronary events and ischemic stroke
(
- Contribution to journal › Article
-
Mark
Association of β-Amyloid Accumulation with Executive Function in Adults with Unimpaired Cognition
(
- Contribution to journal › Article
-
Mark
Association of CSF Aβ38Levels with Risk of Alzheimer Disease-Related Decline
(
- Contribution to journal › Article
-
Mark
β-Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
Decreased Pain Sensitivity and Alterations of Cerebrospinal Fluid and Plasma Inflammatory Mediators After Total Hip Arthroplasty in Patients with Disabling Osteoarthritis
(
- Contribution to journal › Article
-
Mark
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
(
- Contribution to journal › Article
-
Mark
Prevalence and Ascertainment of Dementia Cases in the Malmö Diet and Cancer Study
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article
-
Mark
Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
(
- Contribution to journal › Article
-
Mark
Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Components of gait in people with and without mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Alzheimer Disease : Standard of Diagnosis, Treatment, Care, and Prevention
(
- Contribution to journal › Article
-
Mark
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE 4 carriers
(
- Contribution to journal › Article
-
Mark
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults : Effects of Alzheimer's Disease Pathology and Cognitive Decline
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain : associations with pain severity and central sensitization
(
- Contribution to journal › Article
-
Mark
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders
(
- Contribution to journal › Article
-
Mark
Tau pathology mediates age effects on medial temporal lobe structure
(
- Contribution to journal › Article
-
Mark
Inter-modality assessment of medial temporal lobe atrophy in a non-demented population : application of a visual rating scale template across radiologists with varying clinical experience
(
- Contribution to journal › Article
-
Mark
Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease : towards clinical implementation
(
- Contribution to journal › Scientific review
-
Mark
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline
(
- Contribution to journal › Article
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease : a literature review
(
- Contribution to journal › Scientific review
-
Mark
Empirical pathological staging and subtyping of TDP-43 proteinopathies
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
CenTauRz : A standardized quantification of tau PET scans
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
(
- Contribution to journal › Article
-
Mark
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
(
- Contribution to journal › Article
-
Mark
Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) : A Report of an International Research Collaboration Network
(
- Contribution to journal › Scientific review
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
-
Mark
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration
(
- Contribution to journal › Article
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
(
- Contribution to journal › Article
- 2021
-
Mark
Biomarkers for neurodegenerative diseases
(
- Contribution to journal › Scientific review
-
Mark
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Management of Alzheimer's disease takes a leap forward
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Association between Apolipoprotein e ϵ2 vs ϵ4, Age, and β-Amyloid in Adults without Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
(
- Contribution to journal › Article
-
Mark
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Time between milestone events in the Alzheimer's disease amyloid cascade
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
-
Mark
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment
(
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
-
Mark
Neuroligin-1 in brain and CSF of neurodegenerative disorders : investigation for synaptic biomarkers
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(
- Contribution to journal › Article
-
Mark
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study
(
- Contribution to journal › Article
-
Mark
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
(
- Contribution to journal › Article
-
Mark
Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
- 2020
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
(
- Contribution to journal › Scientific review
-
Mark
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
(
- Contribution to journal › Letter
-
Mark
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions : implications for cutoffs regarding cognitive impairment
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
The A4 study : β-amyloid and cognition in 4432 cognitively unimpaired adults
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden
(
- Contribution to journal › Article
-
Mark
Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment
2020) In European Radiology(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding
(
- Contribution to journal › Article
-
Mark
Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia
(
- Contribution to journal › Article
-
Mark
Medial temporal atrophy in preclinical dementia : Visual and automated assessment during six year follow-up
(
- Contribution to journal › Article
-
Mark
The implications of different approaches to define AT(N) in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Relationship between cortical iron and tau aggregation in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Apathy and anxiety are early markers of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
(
- Contribution to journal › Article
-
Mark
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
(
- Contribution to journal › Article
-
Mark
Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype
(
- Contribution to journal › Article
-
Mark
Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Biomarker profiling beyond amyloid and tau : cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults
(
- Contribution to journal › Article
-
Mark
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration : A translatable marker of synaptic degeneration
(
- Contribution to journal › Article